HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM March 2, 2026 0 Intellia Therapeutics Announces Q4 and Full-Year 2025 Financial Results and Business Updates February 26, 2026 0 Novo Nordisk Announces Significant Reduction in US List Price for Wegovy®, Ozempic® and Rybelsus®, Building on Continued Efforts to Expand Access February 24, 2026 0 Merck Evolves Human Health Operating Structure to Support Portfolio Execution February 23, 2026 0